Influence of ABCB1 (P-glycoprotein) haplotypes on nortriptyline pharmacokinetics and nortriptyline-induced postural hypotension in healthy volunteers

British Journal of Clinical Pharmacology

Volumn 73, Issue 4, 2012, Pages 619-628

  Jensen, Berit Packert ^a   Roberts, Rebecca Lee ^a,b   Vyas, Ritva ^a   Bonke, Gitte ^a   Jardine, David L ^a   Begg, Evan James ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

ABCB1; Nortriptyline; P glycoprotein; Postural hypotension; Tricyclic antidepressants

Indexed keywords

10 HYDROXYNORTRIPTYLINE; MULTIDRUG RESISTANCE PROTEIN 1; NORTRIPTYLINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE; BODY POSTURE; DNA POLYMORPHISM; FEMALE; HAPLOTYPE; HEART RATE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; ORTHOSTATIC HYPOTENSION; PLETHYSMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS, TRICYCLIC; AREA UNDER CURVE; BLOOD PRESSURE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HAPLOTYPES; HEART RATE; HUMANS; HYPOTENSION, ORTHOSTATIC; MALE; MIDDLE AGED; NORTRIPTYLINE; P-GLYCOPROTEIN; PEDIGREE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84858168397     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2011.04126.x     Document Type: Article

References (31)

1. Baldessarini RJ. Drug therapy of depression and anxiety disorders. In: Goodman and Gilman's The Pharmacological Basis of Therapeutics, 11th edn. eds Brunton L, Lazo J, Parker K. New York, NY: McGraw-Hill Companies, Inc, 2006; 429-59.
2. Dollery C, ed. Therapeutic Drugs, 2nd edn. Edinburgh: Churchill Livingstone, 1999.
3. Breyer-Pfaff U. The metabolic fate of amitriptyline, nortriptyline and amitriptylinoxide in man. Drug Metab Rev 2004; 36: 723-46.
4. Aronson J, ed. Meyler's Side Effects of Drugs, 15th edn. Amsterdam: Elsevier, 2006.
5. Roberts RL, Joyce PR, Mulder RT, Begg EJ, Kennedy MA. A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression. Pharmacogenomics J 2002; 2: 191-6.
6. Hodges LM, Markova SM, Chinn LW, Gow JM, Kroetz DL, Klein TE, Altman RB. Very important pharmacogene summary. Pharmacogenet Genomics 2011; 21: 152-61.
7. Leschziner GD, Andrew T, Pirmohamed M, Johnson MR. ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. Pharmacogenomics J 2007; 7: 154-79.
8. Ejsing T, Hasselstrøm J, Linnet K. The influence of P-glycoprotein on cerebral and hepatic concentrations of nortriptyline and its metabolites. Drug Metab Drug Interact 2006; 21: 139-62.
9. Grauer MT, Uhr M. P-glycoprotein reduces the ability of amitriptyline metabolites to cross the blood brain barrier in mice after a 10-day administration of amitriptyline. J Psychopharmacol 2004; 18: 66-74.
10. Uhr M, Grauer MT, Yassouridis A, Ebinger M. Blood-brain barrier penetration and pharmacokinetics of amitriptyline and its metabolites in p-glycoprotein (ABCB1AB) knock-out mice and controls. J Psychiatr Res 2007; 41: 179-88.
11. Uhr M, Steckler T, Yassouridis A, Holsboer F. Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to MDR1a P-glycoprotein gene disruption. Neuropsychopharmacology 2000; 22: 380-7.
12. Kroetz DL, Pauli-Magnus C, Hodges LM, Huang CC, Kawamoto M, Johns SJ, Stryke D, Ferrin TE, DeYoung J, Taylor T, Carlson EJ, Herskowitz I, Giacomini KM, Clark AG. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 2003; 13: 481-94.
13. Eickbush TH, Moudrianakis EN. The compaction of DNA helices into either continuous supercoils or folded-fiber rods and toroids. Cell 1978; 13: 295-306.
14. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.
15. Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, Schaeffeler E, Eichelbaum M, Brinkmann U, Roots I. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 2001; 69: 169-74.
16. Roberts RL, Kennedy MA. Rapid detection of common cytochrome P450 2D6 alleles in Caucasians. Clin Chim Acta 2006; 366: 348-51.
17. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther 2008; 83: 234-42.
18. Wieling W, Karemaker J. Measurement of heart rate and blood pressure to evaluate disturbances in neurocardiovascular control. In: Autonomic Failure: A Textbook of Clinical Disorders of the Autonomic Nervous System, 4th edn. eds Mathias CJ, Bannister R. Oxford: Oxford University Press, 1999; 196-209.
19. Bonke G, Jensen BP. Fast and sensitive LC-MS/MS assay for quantification of nortriptyline and its active metabolites E- and Z-10-hydroxynortriptyline in human plasma. Bioanalysis 2010; 2: 1553-60.
20. Woillard JB, Rerolle JP, Picard N, Rousseau A, Guillaudeau A, Munteanu E, Essig M, Drouet M, Le Meur Y, Donor MP. P-gp polymorphisms strongly influence renal function and graft loss in a cohort of renal transplant recipients on cyclosporine therapy in a long-term follow-up. Clin Pharmacol Ther 2010; 88: 95-100.
21. Bergmann TK, Brasch-Andersen C, Green H, Mirza M, Pedersen RS, Nielsen F, Skougaard K, Wihl J, Keldsen N, Damkier P, Friberg LE, Peterson C, Vach W, Karlsson MO, Brosen K. Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer. Pharmacogenomics J 2011; 11: 113-20.
22. Sistonen J, Sajantila A, Lao O, Corander J, Barbujani G, Fuselli S. CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet Genomics 2007; 17: 93-101.
23. The European Agency for the Evaluation of Medicinal Products. Note for Guidance on the Investigation of Bioavailability and Bioequivalence. London: Committee for Proprietary medicinal Products, 2001.
24. Georgotas A, McCue R, Friedman E. A placebo-controlled comparison of the effect of nortriptyline and phenelezine on orthostatic hypotension in elderly depressed patients. J Clin Psychopharmacol 1987; 7: 413-6.
25. Kiev A, Masco HL, Wenger TL, Johnston A, Batey SR, Holloman LC. The cardiovascular effecs of bupropion and nortriptyline in depressed outpatients. Ann Clin Psychiatry 1994; 6: 107-15.
26. Freyschuss U, Sjöqvist F, Tuck D, Asberg M. Circulatory effects in man of nortriptyline, a tricyclic antidepressant drug. Eur J Clin Pharmacol 1970; 2: 68-71.
27. Thayssen P, Bjerre M, Kragh-Sørensen P, Møller M, Petersen OL, Kristensen CB, Gram LF. Cardiovascular effects of imipramine and nortriptyline in elderly patients. Psychopharmacology 1981; 74: 360-4.
28. Nair NPV, Amin M, Holm P, Katona C, Klitgaard N, Ng Ying Kin NM, Kragh-Sørensen P, Kühn H, Leek CA, Stage KB. Moclobemide and nortriptyline in elderly depressed patients. A randomized, multicentre trial against placebo. J Affect Disord 1995; 33: 1-9.
29. Giardina E-GV, Johnson LL, Vita J, Bigger JT, Brem RF. Effect of imipramine and nortriptyline on left ventricular function and blood pressure in patients treated for arrhythmias. Am Heart J 1985; 109 (5 Part 1): 992-8.
30. Scalco MZ, de Almeida OP, Hachul DT, Castel S, Serro-Azul J, Wajngarten M. Comparison of risk of orthostatic hypotension in elderly depressed hypertensive women treated with nortriptyline and thiazides versus elderly depressed normotensive women treated with nortriptyline. Am J Cardiol 2000; 85: 1156-8.
31. Roose SP, Laghrissi-Thode F, Kennedy JS, Nelson JC, Bigger JT, Pollock BG, Gaffney A, Narayan M, Finkel MS, McCafferty J, Gergel I. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA 1998; 279: 287-91.